TERRY DENNIS, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: The report by Wharton and colleagues (1) in the July issue on the use of trimethoprim-sulfomethoxazole or pentamidine for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome (AIDS) was a valuable addition to the knowledge on treatment of this disorder. Although the trial appears to have been well designed, I believe the results (20% mortality in the trimethoprim-sulfamethoxazole group compared with 5% in the pentamidine group) are too easily discounted by the authors.
The ñ value of 0.09 did not attain the alpha = 0.05 level; however, when the mortality rate is
DENNIS T. Trimethoprim-Sulfamethoxazole or Pentamidine for Pneumocystis Pneumonia in the Acquired Immunodeficiency Syndrome. Ann Intern Med. ;105:629–630. doi: 10.7326/0003-4819-105-4-629_2
Download citation file:
Published: Ann Intern Med. 1986;105(4):629-630.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use